Cordani Ramona, Pisciotta Livia, Stagnaro Michela, Mancardi Maria Margherita, Lampugnani Elisabetta, Manfredini Luca, Nobili Lino, Veneselli Edvige, De Grandis Elisa
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI), University of Genova, Genova, Italy.
Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Epileptic Disord. 2025 Aug;27(4):660-667. doi: 10.1002/epd2.70031. Epub 2025 May 14.
Alternating Hemiplegia of Childhood (AHC) is a severe channelopathy that manifests before 18 months of age, primarily caused by pathogenic variants in the ATP1A3 gene. It is characterized by recurrent and disabling episodes of plegia, dystonia, dysautonomia, along with chronic neurological features and cardiac arrhythmias. About 50% of AHC patients have epilepsy, and a subset of them may develop refractory or super-refractory status epilepticus. Currently, there are no specific available therapeutic guidelines, particularly for managing life-threatening paroxysmal and epileptic episodes in the Intensive Care Unit (ICU).
This report aims to illustrate a comprehensive treatment approach and clinical management of a young boy with AHC and multiple episodes of super-refractory status epilepticus throughout his lifetime. The patient was diagnosed with AHC at the age of 6 months, carrying the most severe ATP1A3 gene mutation-p.Glu815Lys. Epileptic seizures started at 24 months of age, and after a relatively stable clinical course, he experienced a first super-refractory status epilepticus at the age of 16. Subsequently, he presented two additional episodes of status epilepticus and faced progressive neurological deterioration until death at the age of 20.
AHC management is a substantial challenge due to the coexistence of multiple paroxysmal events, epilepsy, chronic neurological impairments, and the possibility of cardiac abnormalities, including short QTc or cardiac rhythm complications. Tailored treatment and deep knowledge of this complex disease are imperative for effective management.
儿童交替性偏瘫(AHC)是一种严重的离子通道病,在18个月龄前发病,主要由ATP1A3基因突变引起。其特征为反复出现的致残性偏瘫、肌张力障碍、自主神经功能障碍,以及慢性神经功能特征和心律失常。约50%的AHC患者患有癫痫,其中一部分可能发展为难治性或超难治性癫痫持续状态。目前,尚无具体可用的治疗指南,尤其是在重症监护病房(ICU)中管理危及生命的阵发性和癫痫发作方面。
本报告旨在阐述一名患有AHC且一生中多次发生超难治性癫痫持续状态的小男孩的综合治疗方法和临床管理。该患者6个月大时被诊断为AHC,携带最严重的ATP1A3基因突变-p.Glu815Lys。癫痫发作始于24个月龄,在经历相对稳定的临床病程后,他在16岁时首次出现超难治性癫痫持续状态。随后,他又出现了两次癫痫持续状态发作,并面临进行性神经功能恶化,直至20岁死亡。
由于多种阵发性事件、癫痫、慢性神经功能损害以及心脏异常(包括短QTc或心律并发症)的共存,AHC的管理是一项重大挑战。针对这种复杂疾病进行量身定制的治疗并深入了解其情况对于有效管理至关重要。